Jan 19, 2015
Farmak adds Metakos pharmaceutical drug to its oncology portfolio
Farmak, a leader of the domestic pharmaceutical industry, continues extending the oncology line of pharmaceutical products. Thus, Metakos, a new drug, is added to the Company’s portfolio.
This medicinal product is produced in the form of concentrate for solution for infusion (vial, 5 ml, No 1). Metakos contains zoledronic acid as active agent.
The medicinal product is prescribed for:
- preventive treatment of symptoms attributable to osseous lesion (pathologic fractures, constriction injury of vertebrarium, complications after surgical interference and XRT or hypercalcemia caused by malignant tumor) in patients suffering from malignant neoplasms at late stages;
- treatment of hypercalcemia caused by malignant tumor.
It is worth to remind that Farmak’s portfolio of pharmaceutical drugs for treatment of oncological diseases includes such products as Letromara (letrozole as active agent), Androfarm (cyproterone as active agent) and Flutafarm (flutamide as active agent).
More news
Future Skills: How Farmak Opens the Path to a Successfu...
On April 2 in Kyiv, Farmak, a leader of the Ukrainian pharmaceutical market, held its second student forum, PRO Future. Around 200 students from chemical, pharmaceutical, biotechnological, and engineering specialties, representing various universities and cities across the country, joined the event. Students gathered to reflect, together with leading experts...
Apr 06, 2026
